J Trauma Acute Care Surg:羊膜治疗烧伤伤口的疗效和可行性

2021-09-09 MedSci原创 MedSci原创

烧伤给社会带来了巨大的经济负担,而且伤口的处理也非常困难。临床经验表明,羊膜(AM)是一种经济而有效的烧伤生物敷料。然而,很少有关于这种用途的系统回顾或荟萃分析发表。近日,发表于J Trauma Ac

烧伤给社会带来了巨大的经济负担,而且伤口的处理也非常困难。临床经验表明,羊膜(AM)是一种经济而有效的烧伤生物敷料。然而,很少有关于这种用途的系统回顾或荟萃分析发表。近日,发表于J Trauma Acute Care Surg的一项荟萃分析评估了AM敷料在烧伤伤口的作用。

2020年3月对PubMed、Cochrane、Embase和Web of Science数据库进行了系统搜索,找出比较AM与其他敷料(如磺胺嘧啶银、聚氨酯膜和蜂蜜)对比的随机对照试验。对于皮肤移植的伤口,比较了AM覆盖的皮肤移植和传统的固定的皮肤移植。疗效分析所关注的结果包括伤口感染、疼痛、瘙痒、疤痕和愈合时间。在可行性分析中,我们评估了各治疗组的不良事件数量、因不良反应而退出的比率、治疗费用和患者的接受程度。

 

最终,研究人员在审查中发现了11项随机对照试验,包括816名参与者。分析结果显示,在治疗烧伤伤口方面,羊膜治疗比传统方法、磺胺嘧啶银和聚氨酯膜更有效,但AM似乎不如蜂蜜有效。在纳入的文章中没有描述与AM有关的疾病传播或不良反应的报告。

综上,羊膜对治疗烧伤伤口有有益的作用;但是,证据需要通过进一步强有力的随机对照试验来加强。

 

原始出处:

 

Chao Yang, et al., Efficacy and feasibility of amniotic membrane for the treatment of burn wounds: A meta-analysis. J Trauma Acute Care Surg. 2021 Apr 1;90(4):744-755. doi: 10.1097/TA.0000000000003050.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1689264, encodeId=2e27168926460, content=<a href='/topic/show?id=3b001e77444' target=_blank style='color:#2F92EE;'>#Trauma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17774, encryptionId=3b001e77444, topicName=Trauma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c528776777, createdName=siiner, createdTime=Sat Jan 01 20:39:16 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022966, encodeId=09172022966c9, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Dec 13 01:39:16 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657553, encodeId=ddfd165e55338, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Nov 07 17:39:16 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346832, encodeId=28dd13468320a, content=<a href='/topic/show?id=0c96191eba' target=_blank style='color:#2F92EE;'>#Acute#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1917, encryptionId=0c96191eba, topicName=Acute)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sat Sep 11 14:39:16 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033134, encodeId=83a3103313438, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Sep 10 02:39:16 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2022-01-01 siiner
  2. [GetPortalCommentsPageByObjectIdResponse(id=1689264, encodeId=2e27168926460, content=<a href='/topic/show?id=3b001e77444' target=_blank style='color:#2F92EE;'>#Trauma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17774, encryptionId=3b001e77444, topicName=Trauma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c528776777, createdName=siiner, createdTime=Sat Jan 01 20:39:16 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022966, encodeId=09172022966c9, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Dec 13 01:39:16 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657553, encodeId=ddfd165e55338, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Nov 07 17:39:16 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346832, encodeId=28dd13468320a, content=<a href='/topic/show?id=0c96191eba' target=_blank style='color:#2F92EE;'>#Acute#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1917, encryptionId=0c96191eba, topicName=Acute)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sat Sep 11 14:39:16 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033134, encodeId=83a3103313438, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Sep 10 02:39:16 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1689264, encodeId=2e27168926460, content=<a href='/topic/show?id=3b001e77444' target=_blank style='color:#2F92EE;'>#Trauma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17774, encryptionId=3b001e77444, topicName=Trauma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c528776777, createdName=siiner, createdTime=Sat Jan 01 20:39:16 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022966, encodeId=09172022966c9, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Dec 13 01:39:16 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657553, encodeId=ddfd165e55338, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Nov 07 17:39:16 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346832, encodeId=28dd13468320a, content=<a href='/topic/show?id=0c96191eba' target=_blank style='color:#2F92EE;'>#Acute#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1917, encryptionId=0c96191eba, topicName=Acute)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sat Sep 11 14:39:16 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033134, encodeId=83a3103313438, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Sep 10 02:39:16 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2021-11-07 bsmagic9140
  4. [GetPortalCommentsPageByObjectIdResponse(id=1689264, encodeId=2e27168926460, content=<a href='/topic/show?id=3b001e77444' target=_blank style='color:#2F92EE;'>#Trauma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17774, encryptionId=3b001e77444, topicName=Trauma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c528776777, createdName=siiner, createdTime=Sat Jan 01 20:39:16 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022966, encodeId=09172022966c9, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Dec 13 01:39:16 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657553, encodeId=ddfd165e55338, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Nov 07 17:39:16 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346832, encodeId=28dd13468320a, content=<a href='/topic/show?id=0c96191eba' target=_blank style='color:#2F92EE;'>#Acute#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1917, encryptionId=0c96191eba, topicName=Acute)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sat Sep 11 14:39:16 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033134, encodeId=83a3103313438, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Sep 10 02:39:16 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2021-09-11 bshuang
  5. [GetPortalCommentsPageByObjectIdResponse(id=1689264, encodeId=2e27168926460, content=<a href='/topic/show?id=3b001e77444' target=_blank style='color:#2F92EE;'>#Trauma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17774, encryptionId=3b001e77444, topicName=Trauma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c528776777, createdName=siiner, createdTime=Sat Jan 01 20:39:16 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022966, encodeId=09172022966c9, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Dec 13 01:39:16 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657553, encodeId=ddfd165e55338, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Nov 07 17:39:16 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346832, encodeId=28dd13468320a, content=<a href='/topic/show?id=0c96191eba' target=_blank style='color:#2F92EE;'>#Acute#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1917, encryptionId=0c96191eba, topicName=Acute)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sat Sep 11 14:39:16 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033134, encodeId=83a3103313438, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Sep 10 02:39:16 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2021-09-10 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

陈劲松: 我在烧伤科做医生

我在烧伤科做医生

PRS:提高治疗效率和患者生活质量,针对烧伤后神经疼痛成因来镇痛!

该研究提出了由直接神经损伤、神经压迫、电损伤和继发于全身损伤的神经功能障碍组成的分类方法,可指导患者的治疗和研究方法,以改善烧伤相关神经疼痛的疼痛结局。

Br J Surg:负压伤口疗法作为儿童小面积热烧伤辅助疗法的有效性

负压伤口疗法(NPWT)在烧伤急性期的疗效仍不清楚。近日,发表于Br J Surg的一项双臂单中心RCT研究比较了标准的Acticoat™和Mepitel™敷料与联合Actic

Cell Death Dis:烧伤后脂肪褐变引发肝脂肪变

烧伤患者会经历体内高代谢,进而会出现肝脂肪变性,这与受伤后发生肝衰竭及不良预后有关。而且烧伤患者还会经历白色脂肪组织(WAT)褐色变,这与烧伤后的恶病质调节和持续的高代谢有关。尽管烧伤后常出现肝脂肪变性和WAT褐色变两种临床表现,但对其潜在机制仍知之甚少。在本研究中,研究人员发现烧伤所引起的WAT褐色变及其相关的脂解作用的增加会导致小鼠肝脂肪变性的加速进展。敲除白介素6(IL-6)和解偶联蛋白1(

Arch Phys Med Rehabil:虚拟现实和任务导向训练对手部烧伤小儿患者功能和活动表现的影响

手部功能是决定小儿手部烧伤(PHB)生活质量的关键因素之一。发表于Arch Phys Med Rehabil的一项随机对照试验评估了运动感应、免提游戏设备和任务导向训练(TOT)项目对改善小儿手部烧伤

烧伤后颏颈胸瘢痕挛缩患者右美托咪定镇静纤支镜引导下经鼻气管插管的体会

颏、颈、胸重度烧伤患者,临床表现为颈部瘢痕挛缩严重,下颌与前胸瘢痕粘连,患者张口困难,后仰受限。此类患者存在面罩通气困难,声门显露困难,气道表麻困难等问题,严重影响手术,威胁患者健康,实施气管内插管对麻醉医生是严峻的挑战。山东大学附属省立医院麻醉科近期采用自制的OLYMPUSLF-DP型号纤支镜气道内表麻设备先实施气管内表麻,然后再使用右美托咪定镇静,纤支镜引导下成功完成经鼻气管插管,插管过程患者